your badges 52W Range $1–$7 2% of range Analyst Rating STRONG BUY 8 analysts Price Target · P/E · ROE -193.9% Net Profit Margin ·

NCNA Stock Snapshot Price, market cap, P/E, EPS, ROE, debt/equity, 52-week range

03
Price $1.09
EPS $0.00
ROE -193.9%
52W Range $1–$7

NCNA Stock Price Chart Daily OHLCV with technical indicators — pan, zoom, and customize your view

04
range
bars

Bar granularity adapts to the selected period — hover the chart to see open/high/low/close for a bar.

Stock splits 2
Ex-date Split Type
Aug. 11, 2025 1-for-200 Reverse
April 16, 2024 1-for-25 Reverse

10-Year Performance Revenue, net income, margins and EPS trends

06
EPS$0.00
2021-12-31 → 2025-12-31
Free Cash Flow$-7M
2017-12-31 → 2025-12-31
Valuation & Ratios 07–12

Valuation P/E, P/S, P/B, EV/EBITDA ratios — is the stock expensive or cheap?

No data for this ratio group yet

Not enough fundamentals data to compute this ratio group yet.

value · ≈ 5Y avg · industry median · verdict relative to median

Earnings History EPS actual vs estimate, surprise %, beat rate, next earnings date

14
Avg Surprise -19.0%
Next Report Nov 11, 2026
PeriodReportEPS ActualEPS EstSurprise
Sept. 30, 2024 $-350.00 $-545.51 35.8%
June 30, 2024 $-600.00 $-369.08 -62.6%
March 31, 2024 $-650.00 $-564.79 -15.1%
Dec. 31, 2023 $-700.00 $-522.30 -34.0%

Full Fundamentals All metrics by year — income statement, balance sheet, cash flow

15
Income Statement 11
Metric Trend 2025202420232022202120202019201820172016
R&D Expense $13M$18M$25M$36M$37M$26M$20M$17M$18M$8M
Operating Income $-20M$-23M$-33M$-39M$-48M$-36M$-27M$-19M$-26M$-8M
Interest Expense $13M$0$0·····$2M·
Interest Income $386.0K$358.0K$754.0K$669.0K$103.0K$246.0K$1M$1M$208.0K$283.0K
Pretax Income $-31M$-22M$-32M$-38M$-48M$-36M$-26M$-18M$-25M$-8M
Income Tax $-1M$-3M$-4M$-6M$-7M$-5M$-4M$-4M$-2M$-2M
Net Income $-29M$-19M$-28M$-32M$-41M$-31M$-21M$-14M$-23M$-6M
EPS (Basic) $0.00$-0.26$-0.53$-0.61$-0.78·····
EPS (Diluted) $0.00$-0.26$-0.53$-0.61$-0.78·····
Shares (Basic) 11,231,520,00074,191,00052,573,00052,235,00052,041,00037,882,00032,327,00031,972,00026,069,00024,107,000
EBITDA $-20M$-23M$-33M$-39M$-48M$-36M$-27M$-19M$-26M·
Balance Sheet 10
Metric Trend 2025202420232022202120202019201820172016
Cash & Equivalents $24M$7M$17M$42M$60M$87M$52M$77M$87M$20M
Receivables $849.0K$922.0K$3M$4M$4M$5M$5M$2M$3M·
Current Assets $27M$12M$25M$55M$72M$102M$65M$84M$94M$26M
PP&E (Net) $658.0K$197.0K$521.0K$866.0K$851.0K$1M$1M$427.0K$358.0K$18.0K
Intangibles $2M$2M$2M$2M$2M$5M$4M$3M$2M$1M
Total Assets $30M$15M$28M$58M$77M$108M$70M$87M$96M$27M
Current Liabilities $5M$9M$13M$19M$12M$8M$6M$6M$3M$2M
Total Liabilities $6M$9M$13M$20M$12M$9M$7M$6M$3M$2M
Retained Earnings $-252M$-224M$-208M$-181M$-150M$-111M$-80M$-59M$-45M$-22M
Stockholders' Equity $24M$6M$15M$39M$66M$99M$64M$82M$93M$25M
Cash Flow 6
Metric Trend 2025202420232022202120202019201820172016
Operating Cash Flow $-7M$-19M$-26M$-23M$-24M$-22M$-24M$-12M$-9M$-9M
CapEx $0$4.0K$4.0K$12.0K$64.0K$361.0K$46.0K$210.0K$370.0K$15.0K
Investing Cash Flow $159.0K$79.0K$3M$120.0K$-4M$-1M$-145.0K$-651.0K$-933.0K$15M
Financing Cash Flow $25M$8M$-53.0K$-161.0K$-98.0K$62M$-47.0K$207.0K$78M$200.0K
Free Cash Flow $-7M$-19M$-26M$-23M$-24M$-22M$-24M$-12M$-9M·
Levered FCF $-20M·······$-11M·
Profitability 3
Metric Trend 2025202420232022202120202019201820172016
ROA -131.6%-89.2%-64.2%-47.2%-43.8%-34.5%-27.2%-15.1%-37.4%·
ROE -193.9%-182.3%-103.5%-61.6%-49.2%-37.7%-29.5%-15.8%-38.9%·
ROIC -79.5%-324.1%-190.0%-84.6%-62.0%-31.1%-35.1%-18.0%-24.9%·
Liquidity & Solvency 3
Metric Trend 2025202420232022202120202019201820172016
Current Ratio 5.61.42.02.86.112.510.515.032.2·
Quick Ratio 5.20.91.62.45.511.39.214.329.7·
Interest Coverage -1.6·······-14.3·
Per Share 1
Metric Trend 2025202420232022202120202019201820172016
EPS (TTM) $0.00$-0.26$-0.53$-0.61$-0.78·····
Valuation (TTM) 3
Metric Trend 2025202420232022202120202019201820172016
Net Income TTM $-29M$-19M$-28M$-32M$-41M$-31M$-21M$-14M$-23M·
P/E ·-915.4-2792.5-5409.8-15256.4·····
Earnings Yield 0.00%-0.11%-0.04%-0.02%-0.01%·····

Most recent period on the left · null values shown as ·

Financial Statements Income statement, balance sheet, cash flow — annual, last 5 years

16
Metric 2025-12-312024-12-312023-12-312022-12-312021-12-31
Net Income $-29M $-19M $-28M $-32M $-41M
Diluted EPS $0.00 $-0.26 $-0.53 $-0.61 $-0.78

Institutional owners (13F) 10 filers · $143K total · As of June 30, 2026

17

Institutions that report holding this stock in their quarterly SEC Form 13F. Long positions only; a single filer may appear twice for separate option legs. Large offsetting put/call legs typically reflect market-making or hedged inventory, not directional conviction.

Holders 10
Value held $143K
New positions 4
Exited positions 2
Institutional activity — Q2 2026 vs prior quarter
New positions Exited positions Increased Decreased Net shares change
4 (+1 vs prior Q) 2 (-2 vs prior Q) 3 (+3 vs prior Q) 0 (-3 vs prior Q) +54K

Compared to Q1 2026. SEC Form 13F filings are due within 45 days of quarter-end plus a short buffer for late filers — quarters still inside that window are skipped in favor of the most recent fully-reported pair.

Institution Value Shares % of tracked 13F Type
StoneX Group Inc. $71,510 47,043 50.02% Shares
CITADEL ADVISORS LLC $41,190 27,099 28.81% Shares
Glass Jacobson Investment Advisors llc $22,800 15,000 15.95% Shares
RHUMBLINE ADVISERS $7,139 4,698 4.99% Shares
CITIGROUP INC $286 188 0.20% Shares
HRT FINANCIAL LP $25 16,870 0.02% Shares
Caitong International Asset Management Co., Ltd $8 5 0.01% Shares
MORGAN STANLEY $3 2 0.00% Shares
SBI Securities Co., Ltd. $2 1 0.00% Shares
ACADIAN ASSET MANAGEMENT LLC $0 2 0.00% Shares

Activists & 5%+ owners 6 positions

18

Investors who filed SEC Schedule 13D — beneficial ownership above 5% with an intent to influence the issuer (activist stakes, board campaigns, M&A). Each row shows the most recent known state of that filer's position.

Filer Filed Stake Status Purpose Filing
Hugh S. Griffith March 18, 2026 12.00% Initial filing Passive investment SEC
Sofinnova Venture Partners VIII, L.P., Sofinnova Management VIII, L.L.C., Sofinnova Venture Partners X, L.P., Sofinnova Management X, L.P., Sofinnova Management X-A, L.L.C., Dr. James I. Healy, Dr. Maha Katabi Feb. 25, 2025 0.10% Amendment Passive investment SEC
Sofinnova Capital VI FCPR, Sofinnova Partners SAS, Antoine Papiernik, Henrijette Richter, Maina Bhaman, Graziano Seghezzi, Anta Gkelou, Karl Naegler Feb. 14, 2025 5.10% Amendment Passive investment SEC
Sofinnova Venture Partners VIII, L.P. (“SVP VIII”), Sofinnova Management VIII, L.L.C. (“SM VIII”), Dr. James I. Healy (“Healy”), Dr. Maha Katabi (“Katabi”), Sofinnova Venture Partners X, L.P. (“SVP X”), Sofinnova Management X, L.P. (“SM X LP”), Sofinnova Management X- A , L.L.C. (“SM X LLC”) ×4 filings Feb. 27, 2024 · Initial filing Passive investment SEC
Sofinnova Capital VI FCPR (“SC VI”), Sofinnova Partners SAS, a French corporation (“SP SAS”), Denis Lucquin (“Lucquin”), Antoine Papiernik (“Papiernik”), Henrijette Richter (“Richter”), Monique Saulnier (“Saulnier”), Graziano Seghezzi (“Seghezzi”) ×6 filings June 15, 2021 · Initial filing · SEC
Abingworth LLP, Abingworth Bioventures VII, LP Sept. 28, 2020 · Initial filing Board campaign SEC

Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.

Company insiders 3 insiders · 2 officers · 1 directors

19
Insider Role Last activity Shares owned Buys 12m Sells 12m Net 12m
Theresa Margaret Ms Bruce Chief Operating Officer April 15, 2026 A · 0 0 $0
Jeffrey D. Bloss Chief Medical Officer June 19, 2026 D · 0 0 $0
Elliott M. Levy Director June 19, 2026 D · 0 0 $0

Insiders from SEC Form 3/4/5 filings; net = open-market P/S only

NCNA Analyst Consensus Bullish and bearish analyst opinions, 12-month price target, upside

21
rating · 8 analysts BUY
3 37.5% Strong Buy
3 37.5% Buy
2 25.0% Hold
0 0.0% Sell
0 0.0% Strong Sell

Peer comparison (GICS sub-industry) Key metrics vs sector peers

22

FY basis, prices as of each company's last fiscal year-end close.

Ticker Market Cap P/E Rev YoY Net Margin ROE Gross Margin
NCNA · · · · -193.9% ·
NIKI · · · · · ·
ROIV $19.95B -51.3 -71.6% -3629.2% -6.5% ·

My Metrics Your personal watchlist — selected rows from Full Fundamentals

26

Pick the metrics that matter to you — click the + next to any row in Full Fundamentals above.

Your selection is saved and follows you across all tickers.

Source: SEC 20-F filed Mar 19, 2026